Key points from article :
Researchers from HepaRegeniX GmbH, Tuebingen University Hospital, and the Mayo Clinic developed a new drug called HRX-215 that aims to treat serious liver diseases.
HRX-215 works by targeting a specific protein (MKK4) that controls how quickly liver cells regenerate.
Animal studies showed that HRX-215 increased liver cell growth and protected them from damage, without affecting healthy livers.
HRX-215 was tested in healthy human volunteers in a Phase I trial and proved to be safe and well-tolerated.
This drug has the potential to revolutionize liver cancer surgery by making it possible to safely remove more diseased tissue and allow the liver to recover quickly.
HRX-215 could also address the shortage of organs available for liver transplantation by making it safer to use smaller portions of donated livers.
